Join
Live feed
·
INSIDERFilingvia Quantisnow
Outlook Therapeutics Inc. logo

Director Haddadin Yezan Munther bought $14,960 worth of shares (34,000 units at $0.44), increasing direct ownership by 1,074% to 37,167 units (SEC Form 4)

ByQuantisnow·Wall Street's wire, on your screen.
OTLK· Outlook Therapeutics Inc.
Health Care
Original source

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track OTLK (Outlook Therapeutics Inc.) and more on Quantisnow.